Screener
Aclaris Therapeutics ACRS Single Reportable — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total research and development project expense(1) | 13,632 | 7,003 | 24,109 | 14,160 |
| Personnel | 3,036 | 2,984 | 6,317 | 5,911 |
| Other research and development(2) | 1,398 | 1,462 | 3,297 | 2,962 |
| Total research and development | 18,066 | 11,449 | 33,723 | 23,033 |
| General and administrative(3) | 6,048 | 5,386 | 12,791 | 11,525 |
| Licensing | 1,235 | 1,335 | 2,628 | 2,345 |
| Revaluation of contingent consideration | 300 | 1,500 | 300 | 1,800 |
| Segment operating loss | $(24,238) | $(18,408) | $(46,430) | $(36,492) |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's single reportable — research and development expense?
- Aclaris Therapeutics (ACRS) reported single reportable — research and development expense of $18.07M in Q2 2026.
- How has Aclaris Therapeutics's single reportable — research and development expense changed year-over-year?
- Aclaris Therapeutics's single reportable — research and development expense increased by 57.8% year-over-year, from $11.45M to $18.07M.
- What does single reportable — research and development expense mean?
- The aggregate expenditure incurred by the segment for research and development activities, including both personnel and operational costs. This is a critical metric for biopharmaceutical companies to track the total burn rate associated with pipeline development. It reflects the overall strategic focus on bringing new therapies to market.
Ask your AI about Aclaris Therapeutics's single reportable — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude